<p>Allogene Therapeutics, Inc.（纳斯达克代码：ALLO - 获取免费报告）的股票在周三的交易中创下了 52 周的新高。该股最高交易价格为 2.57 美元，最后交易价格为 2.4650 美元，交易量为 2017092 股。该股此前收盘价为 2.29 美元。</p>
<p>获取 <strong>Allogene Therapeutics</strong> 的提醒：</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>3 只空头头寸极高的股票</li>
</ul>
<p>几位分析师最近对 ALLO 股票发表了评论。瑞银集团在 1 月 7 日的研究报告中开始覆盖 Allogene Therapeutics 的股票。他们给予该股 “买入” 评级，并设定 8.00 美元的目标价。花旗集团在 1 月 9 日的研究报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”。Wall Street Zen 在周日的报告中将 Allogene Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Citizens Jmp 在 1 月 9 日的报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并设定 5.00 美元的目标价。十位研究分析师对该股给予了 “买入” 评级，两位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，Allogene Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 8.40 美元。</p>
<p><strong>查看我们对 ALLO 的最新分析</strong></p>
<h2>Allogene Therapeutics 上涨 5.5%</h2>
<ul>
<li>你可能想买的 2 个医疗保健领域的降级股票</li>
</ul>
<p>该公司的 50 日移动平均价格为 1.64 美元，200 日移动平均价格为 1.38 美元。该股市值为 5.4272 亿美元，市盈率为-2.46，贝塔值为 0.60。</p>
<h2>Allogene Therapeutics 的内部活动</h2>
<p>在其他 Allogene Therapeutics 的新闻中，首席执行官 David D. Chang 在 2 月 2 日的交易中出售了 95,269 股 Allogene Therapeutics 的股票。股票以平均价格 1.80 美元出售，总价值为 171,484.20 美元。交易后，首席执行官在公司中持有 5,185,862 股，价值 9,334,551.60 美元。这笔交易代表了其持股比例的 1.80% 的减少。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，执行副总裁 Zachary Roberts 在 2 月 2 日的交易中出售了 35,700 股公司的股票。股票以平均价格 1.77 美元出售，总价值为 63,189.00 美元。出售后，执行副总裁持有 581,166 股公司的股票，价值 1,028,663.82 美元。这代表了其持股比例的 5.79% 的减少。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 215,855 股公司股票，价值 378,426 美元。公司内部人士目前持有 13.20% 的股票。</p>
<h2>机构投资者对 Allogene Therapeutics 的看法</h2>
<p>一些大型投资者最近增加或减少了在 ALLO 的持股。Savant Capital LLC 在第三季度收购了 Allogene Therapeutics 的新股份，价值 27,000 美元。Russell Investments Group Ltd.在第三季度将其在 Allogene Therapeutics 的持股增加了 11,159.8%。Russell Investments Group Ltd.现在拥有 21,844 股公司的股票，价值 27,000 美元，此前在上个季度又购买了 21,650 股。Mercer Global Advisors Inc. ADV 在第三季度收购了 Allogene Therapeutics 的新股份，价值约 30,000 美元。Caitong International Asset Management Co. Ltd 在第三季度将其在 Allogene Therapeutics 的持股增加了 5,267.6%。Caitong International Asset Management Co. Ltd 现在拥有 24,047 股公司的股票，价值 30,000 美元，此前在上个季度又收购了 23,599 股。最后，Brighton Jones LLC 在第三季度将其在 Allogene Therapeutics 的持股增加了 81.6%。Brighton Jones LLC 现在拥有 25,168 股公司的股票，价值 31,000 美元，此前在上个季度又购买了 11,311 股。机构投资者持有公司 83.63% 的股票。</p>
<h2>Allogene Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Allogene Therapeutics 是一家临床阶段的生物技术公司，专注于开发同种异体或 “现成” 的嵌合抗原受体 T 细胞（CAR T）疗法，以治疗一系列血液恶性肿瘤和实体肿瘤。该公司利用基因编辑技术生成普遍兼容的工程 T 细胞，旨在克服患者特异性 CAR T 方法的局限性，如生产延迟、产品质量不稳定和治疗抵抗。</p>
<p>该公司的产品管线包括多个针对血癌关键抗原的同种异体 CAR T 候选药物。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票超过 Allogene Therapeutics</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>这让我感到愤怒</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Allogene Therapeutics 吗？</h2>
<p>在考虑 Allogene Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Allogene Therapeutics 并不在名单上。</p>
<p>虽然 Allogene Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

IBBQ

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

ALLO

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>Allogene Therapeutics（纳斯达克代码：ALLO）在交易中达到了新的 52 周高点 2.57 美元，收盘价为 2.4650 美元，成交量超过 200 万股。分析师给予 “买入” 评级，目标价为 8.00 美元，而平均评级为 “适度买入”，共识目标为 8.40 美元。内部交易方面，首席执行官 David D. Chang 和执行副总裁 Zachary Roberts 出售了股份，减少了他们的持股比例。机构投资者持有该股票的 83.63%，显示出对该公司的强烈兴趣，该公司专注于开发用于癌症治疗的异体 CAR T 疗法</p>

<p>Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO - Get Free Report) hit a new 52-week high during trading on Wednesday . The stock traded as high as $2.57 and last traded at $2.4650, with a volume of 2017092 shares trading hands. The stock had previously closed at $2.29.</p>
<div class="lb-trans"><p>Allogene Therapeutics, Inc.（纳斯达克代码：ALLO - 获取免费报告）的股票在周三的交易中创下了 52 周的新高。该股最高交易价格为 2.57 美元，最后交易价格为 2.4650 美元，交易量为 2017092 股。该股此前收盘价为 2.29 美元。</p>
</div><p>Get <strong>Allogene Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Allogene Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>3 Stocks With Sky-High Short Interest Levels</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只空头头寸极高的股票</li>
</ul>
</div><p>Several analysts have recently commented on ALLO shares. UBS Group began coverage on shares of Allogene Therapeutics in a research report on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $8.00 price objective on the stock. Citigroup upgraded shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a research note on Friday, January 9th. Wall Street Zen raised Allogene Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Sunday. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating and set a $5.00 target price for the company in a report on Friday, January 9th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Allogene Therapeutics presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $8.40.</p>
<div class="lb-trans"><p>几位分析师最近对 ALLO 股票发表了评论。瑞银集团在 1 月 7 日的研究报告中开始覆盖 Allogene Therapeutics 的股票。他们给予该股 “买入” 评级，并设定 8.00 美元的目标价。花旗集团在 1 月 9 日的研究报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”。Wall Street Zen 在周日的报告中将 Allogene Therapeutics 的评级从 “卖出” 上调至 “持有”。最后，Citizens Jmp 在 1 月 9 日的报告中将 Allogene Therapeutics 的股票评级从 “市场表现” 上调至 “跑赢大盘”，并设定 5.00 美元的目标价。十位研究分析师对该股给予了 “买入” 评级，两位分析师给予了 “卖出” 评级。根据 MarketBeat 的数据，Allogene Therapeutics 目前的平均评级为 “适度买入”，共识目标价为 8.40 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ALLO</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ALLO 的最新分析</strong></p>
</div><h2>Allogene Therapeutics Trading Up 5.5%</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 上涨 5.5%</h2>
</div><ul>
<li>2 Downgrades in Healthcare You Might Want to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>你可能想买的 2 个医疗保健领域的降级股票</li>
</ul>
</div><p>The firm's fifty day moving average price is $1.64 and its 200 day moving average price is $1.38. The stock has a market capitalization of $542.72 million, a price-to-earnings ratio of -2.46 and a beta of 0.60.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均价格为 1.64 美元，200 日移动平均价格为 1.38 美元。该股市值为 5.4272 亿美元，市盈率为-2.46，贝塔值为 0.60。</p>
</div><h2>Insider Activity at Allogene Therapeutics</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 的内部活动</h2>
</div><p>In other Allogene Therapeutics news, CEO David D. Chang sold 95,269 shares of Allogene Therapeutics stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $1.80, for a total value of $171,484.20. Following the transaction, the chief executive officer owned 5,185,862 shares in the company, valued at $9,334,551.60. This trade represents a 1.80% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, EVP Zachary Roberts sold 35,700 shares of the company's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $1.77, for a total value of $63,189.00. Following the sale, the executive vice president owned 581,166 shares of the company's stock, valued at $1,028,663.82. This represents a 5.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 215,855 shares of company stock worth $378,426. 13.20% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Allogene Therapeutics 的新闻中，首席执行官 David D. Chang 在 2 月 2 日的交易中出售了 95,269 股 Allogene Therapeutics 的股票。股票以平均价格 1.80 美元出售，总价值为 171,484.20 美元。交易后，首席执行官在公司中持有 5,185,862 股，价值 9,334,551.60 美元。这笔交易代表了其持股比例的 1.80% 的减少。该出售在向证券交易委员会提交的文件中披露，文件可通过此链接获取。此外，执行副总裁 Zachary Roberts 在 2 月 2 日的交易中出售了 35,700 股公司的股票。股票以平均价格 1.77 美元出售，总价值为 63,189.00 美元。出售后，执行副总裁持有 581,166 股公司的股票，价值 1,028,663.82 美元。这代表了其持股比例的 5.79% 的减少。该出售的 SEC 文件提供了更多信息。在过去三个月中，内部人士出售了 215,855 股公司股票，价值 378,426 美元。公司内部人士目前持有 13.20% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Allogene Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Allogene Therapeutics 的看法</h2>
</div><p>A number of large investors have recently added to or reduced their stakes in ALLO. Savant Capital LLC acquired a new stake in shares of Allogene Therapeutics in the third quarter worth $27,000. Russell Investments Group Ltd. lifted its position in Allogene Therapeutics by 11,159.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 21,844 shares of the company's stock worth $27,000 after buying an additional 21,650 shares in the last quarter. Mercer Global Advisors Inc. ADV acquired a new position in shares of Allogene Therapeutics during the 3rd quarter worth about $30,000. Caitong International Asset Management Co. Ltd raised its holdings in Allogene Therapeutics by 5,267.6% during the third quarter. Caitong International Asset Management Co. Ltd now owns 24,047 shares of the company's stock worth $30,000 after acquiring an additional 23,599 shares in the last quarter. Finally, Brighton Jones LLC grew its stake in Allogene Therapeutics by 81.6% in the third quarter. Brighton Jones LLC now owns 25,168 shares of the company's stock valued at $31,000 after purchasing an additional 11,311 shares in the last quarter. Institutional investors own 83.63% of the company's stock.</p>
<div class="lb-trans"><p>一些大型投资者最近增加或减少了在 ALLO 的持股。Savant Capital LLC 在第三季度收购了 Allogene Therapeutics 的新股份，价值 27,000 美元。Russell Investments Group Ltd.在第三季度将其在 Allogene Therapeutics 的持股增加了 11,159.8%。Russell Investments Group Ltd.现在拥有 21,844 股公司的股票，价值 27,000 美元，此前在上个季度又购买了 21,650 股。Mercer Global Advisors Inc. ADV 在第三季度收购了 Allogene Therapeutics 的新股份，价值约 30,000 美元。Caitong International Asset Management Co. Ltd 在第三季度将其在 Allogene Therapeutics 的持股增加了 5,267.6%。Caitong International Asset Management Co. Ltd 现在拥有 24,047 股公司的股票，价值 30,000 美元，此前在上个季度又收购了 23,599 股。最后，Brighton Jones LLC 在第三季度将其在 Allogene Therapeutics 的持股增加了 81.6%。Brighton Jones LLC 现在拥有 25,168 股公司的股票，价值 31,000 美元，此前在上个季度又购买了 11,311 股。机构投资者持有公司 83.63% 的股票。</p>
</div><h2>Allogene Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Allogene Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.</p>
<div class="lb-trans"><p>Allogene Therapeutics 是一家临床阶段的生物技术公司，专注于开发同种异体或 “现成” 的嵌合抗原受体 T 细胞（CAR T）疗法，以治疗一系列血液恶性肿瘤和实体肿瘤。该公司利用基因编辑技术生成普遍兼容的工程 T 细胞，旨在克服患者特异性 CAR T 方法的局限性，如生产延迟、产品质量不稳定和治疗抵抗。</p>
</div><p>The company's pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个针对血癌关键抗原的同种异体 CAR T 候选药物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Allogene Therapeutics</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>This makes me furious</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Allogene Therapeutics</li>
<li>华尔街害怕的黄金图表……</li>
<li>美国的 1776 再次发生</li>
<li>这让我感到愤怒</li>
<li>在 2026 年 5 月之前购买这只黄金股票</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Allogene Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Allogene Therapeutics 吗？</h2>
</div><p>Before you consider Allogene Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Allogene Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allogene Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Allogene Therapeutics 并不在名单上。</p>
</div><p>While Allogene Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Allogene Therapeutics 目前在分析师中获得 “适度买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Allogene Therapeutics (NASDAQ:ALLO) Reaches New 1-Year High  - Here's What Happened

Market Beat

Invesco Nasdaq Biotechnology ETF

Allogene Therapeutics

Allogene Therapeutics（纳斯达克股票代码：ALLO）创下新的 1 年高点 - 事情经过如下